marijuana stocks news

Cannabis Science Advances its Move into African Market from HIV to Cancer to the Ebola Virus With a Series of High-Level Meetings in Washington, D.C.

Focused Efforts, Clinical Initiatives, Research Centers, and Furthering Health Education while Establishing Relationships with Multiple Governments and Non-Governmental Organizations

COLORADO SPRINGS, Colo., Nov. 20, 2014 /PRNewswire/ — As part of its multi-pronged move into Africa, the CEO of Cannabis Science, Inc. (CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, joined a delegation lead by Melvin Foote, Founder, President & CEO of the Constituency for Africa (CFA) that met with Congresswoman Karen D. Bass (D-CA) and other key stakeholders.

On Tuesday, Cannabis Science President & CEO Raymond C. Dabney and Director & COO Chad S. Johnson, Esq., joined a 20-person delegation from the CFA that met with Congresswoman Karen D. Bass (D-CA), ranking member of the House Subcommittee on Africa, to discuss U.S. – Africa priorities.

The CFA delegation included Melvin Foote, CFA, Founder, President and CEO; Dr. Roscoe Moore, CFA Interim Chairman and a Special Senior Advisor to Cannabis Science; Dr. Johnnetta B. Cole, Director of the Smithsonian National Museum on African Art; Darius Mans, President of Africare; Mamadou Beye, Director of International Relations for Chevron; former U.S. Ambassador to the Republic of the Congo Dr. Robin R. Sanders; Dr. Monde Muyangwa, Director of the Africa Program of the Woodrow Wilson Center; and other key stakeholders.

“The meetings went very well. From HIV to Cancer to the Ebola virus, it’s clear that Africa should be a focus for the unique cannabinoid therapeutic approaches that Cannabis Science is working to develop. We’re targeting very serious health issues with success and that’s why we’re making some very strategic inroads in the region. We’re very pleased with the reception we’re getting, both in Washington and Africa itself,” said Mr. Dabney.

Priority issues included the renewal of the African Growth and Opportunity Act (AGOA); the U.S. response to the Ebola crisis; the priority of STEM in Africa; Diaspora engagement; and follow-up to the U.S. – Africa Leaders Summit.

Melvin Foote stated, “It is always great to sit down with Congresswoman Karen Bass, who has firmly established herself as a ‘point person’ for Africa in the U.S. Congress. She is on top of the issues, tireless in her pursuit of rational decisions and very much a team builder. CFA feels it an honor and duty to support Congresswoman Bass in her efforts to craft a forward-thinking and responsive agenda for Africa in the United States.”

“I want to congratulate Melvin Foote, Dr. Roscoe Moore, and all the members of the delegation for their ongoing leadership and interest in health and wellness in Africa. Time is of the essence, and their leadership is essential,” added Dabney.

A former Assistant U.S. Surgeon General, Dr. Moore also served as the principal liaison between the U.S. Department of Health and Human Services and various Ministries of Health in Africa, focusing on the development of infrastructure and technical support for the delivery of preventive and curative health needs. In his role with Cannabis Science, Moore serves as an advisor on clinical research and how best to focus company initiatives to address global public health issues.

Mr. Melvin P. Foote is a pioneer in the field of African Affairs. He has over 35 years of experience and has worked in over 30 African countries. And he is recognized as a leading expert on issues related to African policies and programs. Mr. Foote is also the founder of a dynamic CFA-related program called the African American Unity Caucus (AAUC). The AAUC is a broad-based coalition of African-American and African leaders of Africa-focused organizations and groups, to promote pan-Africanism and to link Diaspora leaders in the Western Hemisphere with the African Union (AU), the coordinating forum of the nations of Africa. Further, Mr. Foote serves as an advisor to the African Union’s Ambassador to Washington and as a consultant to the World Bank on African Diaspora issues.

“We’re very excited to announce that Cannabis Science is preparing this aggressive move into the African market with possible acquisitions and clinical initiatives. We’re discussing research centers, furthering health education there, and establishing ongoing relationships with multiple governments and non-governmental organizations,” concluded Mr. Dabney.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

Chad S. Johnson, Esq., Director, COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
1 comment
  1. I feel like what $CBIS is doing with cannabinoid therapeutic development could be huge in the coming years. As more and more people realize what the benefits are, especially to those with serious illness and conditions, lives could really be changed.

Leave a Reply

Your email address will not be published.

You May Also Like

$CANK Secures Big Funding

Monarch America Inc. Secures $1.5 Million Funding Commitment WESTMINSTER, Colo., Dec. 11,…

Harborside Inc. (HBORF) Announces Resolution of Claim

Harborside Inc. Announces Resolution of Claim Harborside Inc. (“Harborside” or the “Company”)…

The Green Organic Dutchman Holdings Ltd. (TGOD.TO) (TGODF) Announces Receipt of Health Canada Cultivation License for Valleyfield, Quebec

The Green Organic Dutchman Announces Receipt of Health Canada Cultivation License for…